若羽臣(003010) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥573,811,489.21, representing a 54.16% increase compared to ¥372,228,772.95 in the same period last year[5] - Net profit attributable to shareholders was ¥27,422,020.97, up 113.88% from ¥12,821,237.60 year-on-year[5] - Basic earnings per share increased by 122.64% to ¥0.1672, compared to ¥0.0751 in the same period last year[5] - Total revenue for the period reached ¥573,811,489.21, a significant increase of 54.2% compared to ¥372,228,772.95 in the previous period[18] - Net profit for the period was ¥27,422,020.97, compared to ¥12,821,237.60 in the previous period, representing a growth of 113.5%[19] - The net profit attributable to the parent company was CNY 27,422,020.97, compared to CNY 12,821,237.60 in the previous period, representing an increase of approximately 113.5%[20] - The total comprehensive income attributable to the parent company was CNY 27,421,778.27, up from CNY 13,039,623.35, indicating a growth of about 110.5%[20] - Basic earnings per share increased to CNY 0.1672 from CNY 0.0751, reflecting a rise of approximately 122.5%[20] Cash Flow - The net cash flow from operating activities decreased by 25.30% to ¥90,741,883.86, down from ¥121,475,841.73 in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 90,741,883.86, down from CNY 121,475,841.73, a decrease of about 25.4%[23] - Cash flow from investing activities showed a net inflow of CNY 25,756,976.39, compared to a net outflow of CNY 10,095,709.41 in the previous period[23] - Cash flow from financing activities resulted in a net inflow of CNY 55,765,929.39, contrasting with a net outflow of CNY 51,824,016.98 last year[23] - The ending cash and cash equivalents balance was CNY 772,437,202.88, up from CNY 395,929,360.45, marking an increase of approximately 95.1%[23] - The company received CNY 661,418,487.51 in cash from sales of goods and services, compared to CNY 457,359,013.66 in the previous period, an increase of about 44.5%[22] - The company paid CNY 249,778,603.70 for goods and services, which is an increase from CNY 188,098,299.47, reflecting a rise of approximately 32.7%[23] - The company reported a cash inflow of CNY 24,391,014.26 from other operating activities, significantly up from CNY 1,563,616.29, indicating a growth of about 1,460.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,657,225,681.95, a 6.86% increase from ¥1,550,851,157.65 at the end of the previous year[5] - Current assets totaled ¥1,325,823,928.34, an increase from ¥1,188,622,286.73, marking a growth of 11.5%[16] - Current liabilities increased to ¥559,340,065.31 from ¥406,578,444.16, reflecting a rise of 37.5%[17] - Cash and cash equivalents rose to ¥762,472,040.77, up from ¥607,081,084.85, indicating a growth of 25.5%[15] - Accounts receivable decreased by 32.69% to ¥134,129,708.23, primarily due to the collection of receivables[8] - Inventory increased to ¥244,523,246.77 from ¥225,714,421.41, showing a growth of 8.3%[16] - Long-term equity investments decreased to ¥67,154,438.70 from ¥91,497,851.19, a decline of 26.6%[16] - Total operating costs amounted to ¥551,236,259.53, up from ¥361,187,177.82, reflecting a year-over-year increase of 52.6%[19] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 14,840[11] - The largest shareholder, Wang Yu, holds 29.20% of the shares, totaling 47,889,867 shares[11] - The second-largest shareholder, Longzi Co., Ltd., holds 9.35% of the shares, totaling 15,337,940 shares[11] - The company has a total of 11,972,467 shares held by Wang Yu, which are unrestricted[12] - The company has a total of 4,387,176 shares held by China Everbright Bank's mixed securities investment fund, which are also unrestricted[12] - The company has not reported any changes in the participation of major shareholders in margin trading activities[12] Legal Proceedings - The company has initiated legal proceedings against Mead Johnson Nutrition (China) Co., Ltd. for a total claim of RMB 18,960,122.18[14] - The company has frozen RMB 35 million of Mead Johnson's bank accounts as part of the legal proceedings[14] - The company is involved in a trademark infringement dispute with Mentholatum (China) Pharmaceutical Co., Ltd., with a claim amounting to RMB 30,524,095.95[14] - The company has been ordered to pay RMB 3 million in damages in the trademark case, with the brand partner covering 50% of the compensation[14] Credit and Borrowing - Short-term borrowings increased by 45.07% to ¥398,182,742.95, mainly due to increased bank credit loans[8] - The company reported a significant increase in credit impairment losses, which rose by 1109.24% to ¥3,182,992.07, mainly due to provisions for receivables[9] - The net cash flow from financing activities was ¥55,765,929.39, a 207.61% increase compared to a negative cash flow of ¥51,824,016.98 in the previous year[9]